CTLA4 and non-small cell lung carcinoma: An elevated mutation burden has been associated with an increased rate of response to anti-CTLA-4 and PD-1 therapies, likely on account of a higher neoantigen burden leading to the antitumor immune response in non-small-cell lung cancer (NSCLC) and UVM (Chan et al., 2015; Rizvi et al., 2015; Chan et al., 2019).